Advice
following a full submission:
brivaracetam (Briviact®) is accepted for restricted use within NHS Scotland.
Indication under review: Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
SMC restriction: for use in patients with refractory epilepsy and treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.
In a pooled analysis of three fixed-dose, placebo-controlled, phase III studies there were statistically significant reductions in the frequency of partial-onset seizures with brivaracetam versus placebo.
Download detailed advice187KB (PDF)
Medicine details
- Medicine name:
- brivaracetam (Briviact)
- SMC ID:
- 1160/16
- Indication:
- Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 11 July 2016